Reneo Pharmaceuticals Analyst Ratings
Reneo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/14/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 10/12/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 365.84% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 365.84% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 257.14% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 381.37% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 179.5% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 132.92% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 334.78% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 334.78% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 598.76% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 288.2% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 272.67% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 598.76% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2023 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/14/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 2023 年 12 月 10 日 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 09/08/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 08/28/2023 | 365.84% | HC Wainwright & Co. | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 07/03/2023 | 257.14% | B of A 类证券 | → 23 美元 | 启动覆盖范围开启 | → 购买 |
| 09/19/2022 | 381.37% | HC Wainwright & Co. | → 31 美元 | 假设 | → 购买 |
| 05/18/2022 | 179.5% | 派珀·桑德勒 | 45 美元 → 18 美元 | 维护 | 超重 |
| 2022 年 3 月 24 日 | 132.92% | SVB Leerink | 25 美元 → 15 美元 | 维护 | 跑赢大盘 |
| 01/27/2022 | 334.78% | 贝尔德 | → 28 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 12/21/2021 | 334.78% | HC Wainwright & Co. | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 11/22/2021 | 598.76% | 拉登堡塔尔曼 | → 45 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 4 月 5 日 | 288.2% | SVB Leerink | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 4 月 5 日 | 272.67% | 杰富瑞集团 | → 24 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 4 月 5 日 | 598.76% | 派珀·桑德勒 | → 45 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的目标价格是多少？
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by William Blair on November 15, 2023. The analyst firm set a price target for $0.00 expecting RPHM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
威廉·布莱尔于2023年11月15日公布了瑞诺制药（纳斯达克股票代码：RPHM）的最新目标股价。该分析公司将目标股价定为0.00美元，预计RPHM将在12个月内降至-100.00％（可能下跌-100.00％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的最新分析师评级是多少？
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by William Blair, and Reneo Pharmaceuticals initiated their outperform rating.
威廉·布莱尔对瑞诺制药（纳斯达克股票代码：RPHM）的最新分析师评级由威廉·布莱尔提供，雷诺制药启动了跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
瑞诺制药（RPHM）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Reneo Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Reneo Pharmicals的最新评级是在2023年11月15日公布的，因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
分析师对瑞诺制药（RPHM）的评级是否正确？
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a initiated with a price target of $0.00 to $0.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $6.44, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Reneo Pharmicals（RPHM）评级是启动的，目标股价为0.00美元至0.00美元。Reneo Pharmicals（RPHM）目前的交易价格为6.44美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。